Trial Profile
Adcetris (Brentuximab Vedotin), Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] With Involved Node Radiation Therapy for High Risk Pediatric Hodgkin Lymphoma (HL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Filgrastim; Prednisolone
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 24 Jul 2023 Planned End Date changed from 1 Oct 2023 to 1 May 2028.
- 03 Feb 2023 Planned End Date changed from 1 Jul 2024 to 1 Oct 2023.
- 07 Apr 2021 The trial was amended to enroll a total of 77 patients to assess improvement in EFS distribution against patient level data from HOD99 using a historical control design.